Sort   by:  
 Page size 
GenomicsLoss of Hepatocyte PI3Ka Protects Mice from Hepatocellular Carcinoma in association with altered lipid metabolism gene expression
Loss of Hepatocyte PI3Ka Protects Mice from Hepatocellular Carcinoma in association with altered lipid metabolism gene expression
PRJNA1292245 | ENA
TranscriptomicsRNAseq of tumor samples from CT26 syngeneic mouse treated with a PI3Ka/d inhibitor (AZD8835)
PI3K inhibitors with differential selectivity to distinct PI3K isoforms have been tested extensively in clinical trials, largely to target tumor epithelial cells. PI3K signaling also regulates the immune system and inhibition of PI3Kdelta modulate the tumor immune microenvironment of pre-clinical mo...
ORGANISM(S): Mus musculus 
2019-01-08 | E-MTAB-7386 | biostudies-arrayexpress
UnknownPTPN14 promotes gastric cancer progression by PI3KA/AKT/mTOR pathway.
Not available
S-EPMC10006225 | biostudies-literature
TranscriptomicsLoss of Hepatocyte PI3Ka Protects Mice from Hepatocellular Carcinoma in association with altered lipid metabolism gene expression
Hepatocellular Carcinoma (HCC) is a disease with an increasing incidence and a high mortality rate; therefore, targeted therapies for HCC are urgently needed. PI3K-AKT-mTORC1 signaling is frequently induced in solid tumors and is associated with tumor progression and with the most aggressive type of...
ORGANISM(S): Mus musculus 
2026-04-30 | GSE302836 | GEO
ProteomicsPI3Kalpha Immunocomplex Identification
Mass Spectrometry Analysis of PI3Ka Immunocomplex via immunoprecipitation and SDS-PAGE separation
ORGANISM(S): Homo sapiens (Human) 
2022-02-16 | PXD021306 | Pride
P85alpha antibody Pi3kalpha Immunoprecipitation Map4 protein 
ProteomicsA high affinity pan-PI3K binding module supports selective targeted protein degradation of PI3Ka
Class I phosphoinositide 3-kinases (PI3Ks) control cellular growth, but are also essential in insulin signaling and glucose homeostasis. Pan-PI3K inhibitors thus generate substantial adverse effects, a reality that has plagued drug development against this target class. We present here evidence that...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2023-12-06 | MSV000093594 | MassIVE
GenomicsRNAseq of tumor samples from CT26 syngeneic mouse treated with a PI3Ka/d inhibitor (AZD8835)
RNAseq of tumor samples from CT26 syngeneic mouse treated with a PI3Ka/d inhibitor (AZD8835)
PRJEB29676 | ENA
ProteomicsHDX-MS analysis of p110a in complex with regulatory subunits
HDX-MS was used to map the changes in conformational dynamics in the catalytic subunit of PI3Ka, p110a, in complex with the following five reguatory subunits: p85a, p85b, p55g, p55a, p50a. Apo and pY activated states were also compared between the three splice variants encoded by PIK3R1. No signific...
ORGANISM(S): Homo sapiens (Human) 
2025-11-20 | PXD069057 | Pride
Hdx-ms Pi3ka P85 
ProteomicsHDX-MS of Activators and Inhibitors of PI3Kalpha
Harnessing the potential beneficial effects of kinase signalling through the generation of direct kinase activators remains an underexplored area of drug development. This also applies to the PI 3-kinase (PI3K) signalling pathway which has been extensively targeted by inhibitors for conditions with ...
ORGANISM(S): Homo sapiens (Human) 
2023-03-06 | PXD037721 | Pride
Pi3ka Ucl-1938-tro Hdx-ms P110a 
UnknownRepression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy.
Not available
S-EPMC6538319 | biostudies-literature
Sort   by:  
 Page size